Skip to main content
. Author manuscript; available in PMC: 2023 Apr 14.
Published in final edited form as: Ann N Y Acad Sci. 2022 Nov 16;1519(1):153–166. doi: 10.1111/nyas.14915

FIGURE 1.

FIGURE 1

(A) Format of a B-Body. CH3 domains with mutations to drive heterodimerization replace one CH1/CL pair. (B) Nonoptimized production of several bispecific B-Body clones is 11 g/L. The final purified yield (also nonoptimized) was 5–6 g/L. (C) Treatment with the murine surrogate of a Treg SNIPER™ cures 4/5 mice at the lowest dose of 0.4 mg/kg dosed once. Higher doses cured all mice.